Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 2915-2924
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.2915
Advances in immunotherapy of M2 macrophages and gastrointestinal stromal tumor
Xiao-Ke Wang, Xin Yang, Tong-Han Yao, Peng-Xian Tao, Guan-Jun Jia, De-Xian Sun, Lin Yi, Yuan-Hui Gu
Xiao-Ke Wang, Xin Yang, Tong-Han Yao, The First School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
Peng-Xian Tao, Yuan-Hui Gu, Department of General Surgery, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China
Guan-Jun Jia, Lin Yi, School of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
De-Xian Sun, Graduate School, Qinghai University, Xining 810016, Qinghai Province, China
Co-corresponding authors: Lin Yi and Yuan-Hui Gu.
Author contributions: Wang XK contributed to original draft preparation; Yang X and Yao TH contributed to image drawing; Jia GJ and Sun DX participated in literature collection; Gu YH, Yi L, and Tao PX revised the manuscript; and all authors wrote, read, and approved the final manuscript. The reasons for designating Gu YH and Yi L as co-corresponding authors are twofold. Gu YH and Yi L were the co-corresponding authors of this manuscript because they discussed and selected topics together and developed the framework of the entire manuscript; after the first draft was completed, they revised and improved the manuscript together and jointly guided the completion of this manuscript.
Supported by the National Natural Science Foundation of China, No. 82160842; and Clinical Research Project of Research Fund of Gansu Provincial Hospital, No. 23GSSYD-17.
Conflict-of-interest statement: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yuan-Hui Gu, Doctor, Chief Doctor, Surgeon, Surgical Oncologist, Department of General Surgery, Gansu Provincial Hospital, No. 204 Donggang West Road, Lanzhou 730000, Gansu Province, China. guyuanh@163.com
Received: March 18, 2024
Revised: May 16, 2024
Accepted: May 28, 2024
Published online: July 15, 2024
Processing time: 116 Days and 4.5 Hours
Core Tip

Core Tip: The place of imatinib in gastrointestinal stromal tumor (GIST) treatment is indisputable, but it has some limitations and is not accepted by all patients. In this review, we summarize the interaction between M2 macrophages and the programmed death receptor-1/programmed death ligand-1 pathway, which can improve the efficacy of imatinib by reactivating or enhancing the anti-tumor effect of the host immune system and provide new ideas for GIST immunotherapy.